Type: Oral
Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Alternative Laboratory Predictors of Outcome
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Clinical Research, Real-world evidence, Biological Processes, Molecular biology
Patients and Methods: Hence, we focused our clinical attention on those CML pts not candidates for a TFR path, having achieved within 6 months, and further maintained, a stable MR3 or less (MR2) by investigating the large LabNet CML database, a network founded by GIMEMA in 2014. This network standardized and harmonized the molecular methodology among 51 laboratories distributed all over Italy for the diagnosis and the molecular residual disease monitoring.
Results: Out of 9,699 pts, 585 met study endpoints and achieved a MR2/MR3 within 6 months with a minimum follow up of 24 months. CML pts received frontline therapy as follows: 219 with IM, 133 with DAS and 233 with NIL. Within 24 months, 375 pts achieved a DMR (MR4, MR4,5), whereas 187 showed a stable MR2/MR3 response and 23 had some molecular fluctuations less than MR2. With the successive follow up > 24 months, 123 out of 187 (66%) achieved a DMR, 59/187 (32%) remained in stable molecular response and 5/187 (2.7%) lost the response. No difference was observed in achieving molecular responses by the three different TKIs. Among the MR2/MR3 cohort the median time to therapy switch was 37 months. Moreover, median observation time (OT) was 5.5 yrs for the total study group (585), 5.5 yrs for the DMR group (375), 5.4 yrs for the stable MR2/MR3 (187) and 4.8 yrs for the MR2 ones (23).
Conclusion: A MR2/MR3 stable response achieved within 24 months seems predictive of a good molecular outcome since 66% of these pts obtained a DMR in the successive follow up of 24 months of. Molecular fluctuations less than MR2, although in pts with a previous obtained MR3, might represent a reliable warning sign.
Disclosures: Galimberti: Roche: Honoraria, Other: support for attending meetings; Incyte: Honoraria; Novartis: Honoraria, Other: support for attending meetings; Jazz: Honoraria, Other: support for attending meetings; AstraZeneca: Honoraria, Other: support for attending meetings; AbbVie: Honoraria, Other: support for attending meetings; Celgene: Honoraria; Pfizer: Honoraria; Janssen: Honoraria. Sorà: Novartis: Research Funding. Soverini: Blueprint Medicines: Honoraria; Incyte Biosciences: Consultancy; Istituto Gentili: Honoraria, Research Funding. Bonifacio: Pfizer: Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Incyte: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees. Martinelli: Novartis: Consultancy; Bristol Myers Squibb (BMS): Consultancy; ARIAD: Consultancy; MSD: Consultancy; Roche: Consultancy; Pfizer: Research Funding. Rosti: Pfizer: Research Funding, Speakers Bureau; Novartis: Speakers Bureau; Incyte: Consultancy, Speakers Bureau. Vignetti: Mattioli Health: Honoraria; Arhea: Honoraria; Edrea: Honoraria; Vertex: Honoraria; Isheo: Honoraria; Novartis: Honoraria; Abbvie: Honoraria; Astrazeneca: Honoraria; Dephaforum SRL: Honoraria. Breccia: GSK: Honoraria; BMS: Honoraria; Abbvie: Honoraria; AOP: Honoraria; Incyte: Honoraria; Pfizer: Honoraria; Novartis: Honoraria. Pane: GSK Incyte Amgen BMS Janssen Jazz Novartis Pfizer: Speakers Bureau; GSK Incyte: Consultancy.